Xilio Therapeutics

Update in progress

XLO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Xilio Therapeutics is a clinical‑stage biotechnology company developing masked immuno‑oncology therapies. Its pipeline includes XTX501, a bispecific PD‑1 / masked IL‑2 for metastatic non‑small cell lung cancer; Efarindodekin alfa, a masked IL‑12 in Phase 2 for advanced solid tumors; and Vilastobart, a tumor‑activated, Fc‑enhanced anti‑CTLA‑4 antibody. Founded in 2016 and based in Waltham, MA.

Company score

Sentiment: 0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.32; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive